Assessment of pulmonary vasoreactivity in children with pulmonary hypertension

Area of Science:

• Pediatric Cardiology
• Pulmonary Hypertension Research
• Diagnostic Testing

Background:

• Pulmonary arterial hypertension (PAH) in children requires tailored treatment strategies.
• Pulmonary vasoreactivity testing is crucial for navigating treatment options in pediatric PAH.
• Advances in understanding and treatment necessitate updated reviews of diagnostic methods.

Purpose of the Study:

• To review milestone and recent studies on pulmonary vasoreactivity testing in children.
• To provide an update on available pulmonary vasodilator agents and response markers.
• To discuss the implications of testing results on pediatric PAH management and long-term outcomes.

Main Methods:

• Comprehensive literature review of studies on pediatric pulmonary vasoreactivity testing.
• Analysis of data on pulmonary vasodilator agents and genetic predictors.
• Evaluation of the impact of testing interpretation on clinical decision-making.

Main Results:

• Emerging data exist on pulmonary vasodilators and genetic predictors for vasoreactivity in pediatric PAH, particularly idiopathic and familial forms.
• Despite improved prognosis due to recent therapies, standardized testing and interpretation remain limited and controversial.
• Responder criteria vary, especially in PAH related to congenital heart defects, often depending on institutional practices.

Conclusions:

• The definition of pulmonary vasoreactivity testing responders is debated, particularly in pediatric PAH associated with congenital heart defects.
• Responder criteria are more consistent for idiopathic pulmonary artery hypertension in children.
• Children identified as responders generally exhibit less severe disease and a better long-term prognosis.